New drug tested for Tough-to-Treat blood cancer

NCT ID NCT03275103

Summary

This early-stage trial tested a new drug called cevostamab in 355 patients whose multiple myeloma had returned or stopped responding to other treatments. The main goal was to find safe dosage levels and understand how the drug moves through the body. Researchers monitored side effects closely, particularly watching for cytokine release syndrome, a known immune reaction to this type of therapy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Alfred Hospital

    Melbourne, Victoria, 3004, Australia

  • City of Hope

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra

    Pamplona/iruña, Navarre, 31008, Spain

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hospital Clinico Universitario de Salamanca

    Salamanca, 37007, Spain

  • Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Mayo Clinic Hospital - Arizona

    Scottsdale, Arizona, 85259, United States

  • Memorial Sloan Kettering

    New York, New York, 10065, United States

  • Mount Sinai Hospital

    New York, New York, 10128, United States

  • Peter MacCallum Cancer Center

    East Melbourne, Victoria, 3022, Australia

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 2M9, Canada

  • Tennessee Oncology - Nashville

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4009, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

  • University of Calgary Cumming School of Medicine

    Calgary, Alberta, T2N 4N2, Canada

  • University of Colorado Denver

    Aurora, Colorado, 80045, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.